https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-24 / Clin. Cancer Res. 2010 Oct;16(20):5067-78
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-24 / Clin. Cancer Res. 2010 Oct;16(20):5067-782010-08-24 00:00:002019-02-15 08:49:24Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-22 / Cancer Biol. Ther. 2010 Aug;10(4):368-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-22 / Cancer Biol. Ther. 2010 Aug;10(4):368-752010-08-22 00:00:002020-01-08 10:10:16Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / Nat. Rev. Immunol. 2010 Aug;10(8):580-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / Nat. Rev. Immunol. 2010 Aug;10(8):580-932010-08-01 00:00:002019-02-15 08:52:58Prostate cancer as a model for tumour immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / BioSystems 2010 Aug;101(2):117-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / BioSystems 2010 Aug;101(2):117-262010-08-01 00:00:002019-02-15 08:40:18Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / Zhonghua Nan Ke Xue 2010 Aug;16(8):698-704
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / Zhonghua Nan Ke Xue 2010 Aug;16(8):698-7042010-08-01 00:00:002019-02-15 08:52:54[Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-27 / Pigment Cell Melanoma Res 2010 Oct;23(5):607-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-27 / Pigment Cell Melanoma Res 2010 Oct;23(5):607-192010-07-27 00:00:002010-07-27 00:00:00Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-19 / Vaccine 2010 Jul;28(32):5153-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-19 / Vaccine 2010 Jul;28(32):5153-602010-07-19 00:00:002019-02-15 08:40:17Human myeloid dendritic cells for cancer therapy: does maturation matter?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-14 / Proc. Natl. Acad. Sci. U.S.A. 2010 Aug;107(31):13824-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-14 / Proc. Natl. Acad. Sci. U.S.A. 2010 Aug;107(31):13824-92010-07-14 00:00:002019-02-15 08:45:27Induction of complete and molecular remissions in acute myeloid leukemia by Wilms‘ tumor 1 antigen-targeted dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-07-07 / Br. J. Haematol. 2010 Sep;150(5):554-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-07-07 / Br. J. Haematol. 2010 Sep;150(5):554-642010-07-07 00:00:002019-02-15 08:50:54Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-29 / J Oncol 2010;2010:179491
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-29 / J Oncol 2010;2010:1794912010-06-29 00:00:002019-02-15 08:53:21Advances in cellular therapy for the treatment of thyroid cancer
